Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross NC guselkumab (Tremfya) Coverage Update…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Guselkumab (Tremfya) — coverage criteria for IV and SC administration

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, site-of-care, dosing limits, and documentation requirements for guselkumab (Tremfya) IV and SC administration across FDA-approved indications (psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease); affects prescribers, infusion centers, and prior authorization reviewers.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyGuselkumab (Tremfya) — coverage criteria for IV and SC administration
    Policy CodePolicy N/A
    Change TypeMaterial revisions (eligibility, IBD objective criteria, pediatric dosing updates)
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of indication-specific requirements, objective evidence for IBD, prior therapy trials or exceptions, and ensure requested units do not exceed indication maximums.
    SourceLink
    POLICY UPDATE CHANGES

    Allowance added for patients currently established on a biologic or systemic immunomodulator agent for the requested indication who have had positive clinical benefit from that agent.

    For CD and UC, removed required trial/failure of conventional therapy and replaced with requirement to demonstrate moderately to severely active disease using symptoms plus objective evidence of active inflammation or other specified criteria.

    Expanded pediatric eligibility for PS and PsA to patients >=6 years who weigh at least 40 kg and updated UC induction dosing to include IV or SC options per FDA label.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4FDA-approved indications included
    365Duration of approval (days)
    J1628HCPCS code listed
    PS/PsA 800; UC/CD 3200Max units (varies)

    Coverage and Medical Necessity Criteria

    Initial Therapy (by indication)

    Covered when ALL of the following are met for the requested indication (each indication has its own nested rules):

    Psoriasis (PS) initial therapy

    • Age/Weight: Patient is >=6 years AND weighs >=40 kgsee age/weight thresholds
    • Prior therapy or exceptions: ONE of: (1) inadequate response to ONE conventional agent used for >=3 months (documentation required); OR (2) intolerance/hypersensitivity to ONE conventional agent (documentation required); OR (3) FDA-labeled contraindication to ALL conventional agents (documentation required); OR (4) severe active PS (e.g., >10% BSA, select locations, intractable pruritus, serious emotional consequences) (documentation required); OR (5) concomitant severe PsA; OR (6) currently established on an FDA-approved biologic/systemic immunomodulator for PS with documented positive clinical benefit (documentation required)

    Psoriatic Arthritis (PsA) initial therapy

    • Age/Weight: Patient is >=6 years AND weighs >=40 kg
    • Prior therapy or exceptions: ONE of: (1) inadequate response to ONE conventional agent (e.g., cyclosporine, leflunomide, methotrexate, sulfasalazine) for >=3 months (documentation required); OR (2) intolerance/hypersensitivity to ONE conventional agent (documentation required); OR (3) FDA-labeled contraindication to ALL conventional agents (documentation required); OR (4) severe active PsA (examples provided) (documentation required); OR (5) concomitant severe PS; OR (6) currently established on an FDA-approved biologic/systemic immunomodulator for PsA with documented positive clinical benefit (documentation required)

    Ulcerative Colitis (UC) initial therapy

    • Age: Patient is >=18 years
    • Evidence of active disease: ONE of: (A) BOTH symptoms consistent with active UC AND objective evidence of active inflammation on endoscopy (e.g., MES, UCEIS) (documentation required); OR (B) Evidence of active inflammation on intestinal ultrasound (IUS) (documentation required); OR (C) Biomarker evidence of inflammation (e.g., elevated FC, CRP, ESR, low albumin) (documentation required); OR (D) Presence of >=1 poor prognostic factor (documentation required); OR (E) corticosteroid-dependence or refractory to oral corticosteroids (documentation required); OR (F) patient currently established on an FDA-approved biologic/systemic immunomodulator for UC with documented positive clinical benefit (documentation required)

    Crohn's Disease (CD) initial therapy

    • Age: Patient is >=18 years
    • Evidence of active disease: ONE of: (A) Symptoms consistent with active CD AND objective evidence of active inflammation on cross-sectional imaging, IUS, or pelvic MRI (e.g., bowel wall thickening, ulceration, fistula, abscess) (documentation required); OR (B) Biomarker evidence of inflammation (e.g., elevated FC, CRP, ESR, low albumin) (documentation required); OR (C) Significant extent of disease or upper GI involvement identified on radiographic or endoscopic assessment (e.g., large/deep mucosal lesions, fistulas, strictures, ileal involvement >40 cm, pancolitis, prior bowel resection) (documentation required); OR (D) corticosteroid-dependence or refractory to oral corticosteroids (documentation required); OR (E) patient currently established on an FDA-approved biologic/systemic immunomodulator for CD with documented positive clinical benefit (documentation required)
    Common requirements across indications: Prescriber is a specialist or has consulted a specialist; patient will not use guselkumab in combination with another biologic/Otezla/Zeposia; no FDA labeled contraindications to guselkumab; TB testing performed per prescribing information and latent TB treated if positive; requested quantity does not exceed maximum units; site-of-care criteria apply for inpatient/outpatient administration; duration of approval = 365 days.

    Site of Care Medical Necessity Criteria

    Site of Care criteria determine whether hospital outpatient/inpatient administration is medically necessary; otherwise administration should occur in home or physician office settings.

    Inpatient administration allowed if above medical necessity criteria met AND inpatient admission is NOT solely for administration.
    Outpatient hospital administration allowed if above medical necessity criteria met AND ONE of: history of severe adverse event to injection/infusion (e.g., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure); OR conditions that increase risk for severe adverse events (e.g., unstable renal function, cardiopulmonary conditions, unstable vascular access); OR history of mild adverse events not managed with pre-medication; OR inability to physically/cognitively adhere to regimen; OR new to therapy (<3 months) or re-initiation scenarios; OR requirement for change in product formulation.
    Default setting: If site-of-care criteria are NOT met, injection or infusion will be administered in a home-based infusion or physician office setting with or without supervision by a certified healthcare professional.

    Use of guselkumab (Tremfya) in combination with another biologic immunomodulator agent, Otezla, or Zeposia is prohibited. The prescriber must ensure the patient will NOT be using guselkumab in combination with these agents as a condition of medical necessity determinations.

    Requests that exceed the maximum units allowed for the duration of approval will not meet criteria. Per the dosing table, the maximum units are PS/PsA: 800 units; UC/CD: 3,200 units, and the requested quantity must not exceed these limits. Additionally, requests that do not meet indication-specific objective disease activity criteria (for IBD indications) or other required clinical criteria are not considered medically necessary.

    Billing Codes and Eligibility

    Covered HCPCS CodesHCPCSCovered
    J1628Guselkumab (Tremfya) HCPCS code as listed
    Age and weight thresholds
    Psoriasis (PS) and Psoriatic Arthritis (PsA) age/weightPatient must be >= 6 years of age AND weigh at least 40 kg
    Ulcerative Colitis (UC) agePatient must be >= 18 years of age
    Crohn's Disease (CD) agePatient must be >= 18 years of age
    Maximum units allowed for duration of approval
    Maximum units — Psoriasis (PS)800 units for the duration of approval
    Maximum units — Psoriatic Arthritis (PsA)800 units for the duration of approval
    Maximum units — Ulcerative Colitis (UC)

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for guselkumab (Tremfya®). Dosing and maximum units will be verified at the time of request (HCPCS J1628). Standard approval duration is 365 days (1 year).

    • Dosing: PS & PsA — 100 mg SC at weeks 0 and 4, then every 8 weeks thereafter
    • Dosing: UC — Induction: 200 mg IV at weeks 0, 4, and 8; OR 400 mg SC at weeks 0, 4, and 8
    • Maximum units: PS 800; PsA 800; UC 3,200; CD 3,200
    Step Therapy

    Step Therapy and Exceptions

    Step therapy requirements apply for plaque psoriasis (PS) and psoriatic arthritis (PsA). Exceptions are allowed for patients who are currently established on another FDA‑approved biologic or systemic immunomodulator for the requested indication and have documented positive clinical benefit.

    • PS & PsA: Trial and inadequate response to ≥1 conventional agent for at least 3 months is required unless exception criteria met

    Definitions and Site-of-Care Justification

    Site-of-care conditions justifying hospital administration
    Inpatient administration — restrictionInpatient administration allowed only when medical necessity criteria are met AND the inpatient admission is NOT solely for administration of the injection/infusion
    Outpatient hospital administration — qualifying reasonsAllowed when medical necessity criteria are met AND one of: history of a severe adverse event to the drug (e.g., anaphylaxis, seizure, thromboembolism, MI, renal failure); conditions increasing risk for severe adverse events (e.g., unstable renal or cardiopulmonary function, unstable vascular access); or history of mild adverse events not managed with pre-medication
    Other outpatient hospital justificationsAllowed when medical necessity criteria are met AND one of: inability to physically/cognitively adhere to regimen; new to therapy (<3 months since initial injection/infusion); re-initiation scenarios (e.g., first injection after ≥6 months off for drugs with <6-month interval, or after ≥1 month gap outside approved interval for drugs with 6-month dosing); requirement for change in product formulation
    Default site-of-care if criteria not metIf Site of Care criteria are not met, administration should occur in home-based infusion or physician office setting (with or without supervision by a certified healthcare professional)

    Clinical Background

    Guselkumab (Tremfya) is an anti–IL‑23 monoclonal antibody available as an intravenous infusion or subcutaneous injection. It is FDA‑approved for plaque psoriasis (PS) and psoriatic arthritis (PsA) in patients aged ≥ 6 years who weigh at least 40 kg, and for ulcerative colitis (UC) and Crohn’s disease (CD) in patients aged ≥ 18 years. Dosing varies by indication (for example, PS and PsA: 100 mg SC at weeks 0 and 4, then every 8 weeks; UC induction: 200 mg IV at weeks 0, 4, and 8 or 400 mg SC at weeks 0, 4, and 8).

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyGuselkumab (Tremfya) — coverage criteria for IV and SC administration
    Policy CodePolicy N/A
    Change TypeMaterial revisions (eligibility, IBD objective criteria, pediatric dosing updates)
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of indication-specific requirements, objective evidence for IBD, prior therapy trials or exceptions, and ensure requested units do not exceed indication maximums.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling Codes and EligibilityProvider Requirements, Prior Authorization, and DocumentationDefinitions and Site-of-Care JustificationClinical Background
    3,200 units for the duration of approval
    Maximum units — Crohn's Disease (CD)3,200 units for the duration of approval
  1. Exception: Current use of an FDA‑approved biologic/systemic immunomodulator with documented benefit — medical record documentation required
  2. Conventional agents examples for PS: acitretin, anthralin, calcipotriene, calcitriol, coal tar products, cyclosporine, methotrexate, pimecrolimus, phototherapy (PUVA or UVB), tacrolimus, tazarotene, topical corticosteroids
  3. Conventional agents examples for PsA: cyclosporine, leflunomide, methotrexate, sulfasalazine
  4. Denial Risk

    Quantity and Combination Restrictions

    Requests that exceed the documented maximum units for the approved duration or that combine guselkumab (Tremfya®) with another biologic immunomodulator or specified agents are not allowed.

    • Combination use with another biologic immunomodulator, Otezla® (apremilast), or Zeposia® (ozanimod) is not permitted
    • Requests exceeding maximum units for the duration of approval will be denied
    • Site of care rules apply for inpatient or outpatient hospital administration requests